<DOC>
	<DOCNO>NCT00161265</DOCNO>
	<brief_summary>This study perform tumor blood sample patient receive breast cancer treatment prior surgery collect stored future research .</brief_summary>
	<brief_title>Tissue Procurement Protocol Patients Undergoing Neoadjuvant Systemic Therapy Breast Cancer</brief_title>
	<detailed_description>This protocol provide systematic approach obtain , catalog , distribute research tissue blood patient receive neoadjuvant systemic therapy localize breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . All patient must primary measurable invasive breast cancer primary tumor intact ( T1 , 2 , 3 , 4 , N , M0 M1 ) . Recurrent disease breast also eligible . 2 . The patient 's clinical plan include neoadjuvant systemic therapy ( chemotherapy , hormonal therapy , biologic therapy ) , prior surgery breast . 3 . The clinical plan patient recurrent M1 disease must include breast surgery neoadjuvant systemic therapy . This would include patient nonbulky M1 disease treat physician feel would benefit local control disease neoadjuvant systemic therapy . 4 . Patients must mammography performed University Michigan , OR outside film review prior enrollment . 5 . All patient require sign inform consent regard experimental purpose research biopsy serum banking , accordance University Michigan Institutional Review Board standard . 1 . Breast tumor measurable modality , include physical examination , mammography , ultrasound . 2 . Tumors diagnose excisional biopsy , incisional biopsy leave measurable disease physical examination , mammography , ultrasound . 3 . Patients must receive prior chemotherapy , hormonal therapy , radiation therapy current breast cancer . Patients receive tamoxifen agent prevention breast cancer may include . 4 . Patients another active systemic malignancy past year .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>